CERE-120 Phase II trials fall of 2006
For people who are avoiding dbs and looking for a treatment that may provide neuroregeneration -- watch for the upcoming the CERE-120 phase II gene therapy multi-center trial coming later this fall of 2006.
They use neurturin -- a neurotrophic factor. Phase I safety trial was a success, and details will be published soon. ceregene press releases about phase I pdf presentation of phase I study design jean |
Jeanb, can you expand on the comment that
Phase 1 was a success ?
Aftermathman. |
Cere-120 Phase I a success
Yes it was a success - I dialed in for an FDA webcast where ceregene presented results of phase I and also generally outlined their plans for phase II. Full details of the Phase I trial will be published (or presented - can't remember which) this month - October 2007. It sounds very promising.
Jean :o |
webcast site
Neither the webcast nor the minutes are linked yet - but i think they will be eventually. The meeting took place 9/20/06
This link goes to the web page where you will (eventually) see the link to the webcast about cere-120 phase I and plans for phase II. Jean |
Jeanb, thats great news, thankyou
for a good start to my day.
Aftermathman |
notes on ceregene meeting at NIH
Removed as author was worried about accuracy or misinterpretation, but do try to watch it when it comes online- it was quite interesting watching the questioning and defending of this trial. The trial has champions; wheras the Amgen champion of GNDF passed away of a heart attack. Watching this made me wonder how well it was defended.
paula |
hope
Cere-120 gives me hope for a neurorestorative treatment.
Yes, it's truly a pity about GDNF (which we're still fighting for). But hopefully cere-120 (neurturen) will fill that void for most of us. Jean |
All times are GMT -5. The time now is 08:27 AM. |
Powered by vBulletin Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.
vBulletin Optimisation provided by
vB Optimise v2.7.1 (Lite) -
vBulletin Mods & Addons Copyright © 2024 DragonByte Technologies Ltd.